Guardant Health Inc. (GH)
Summary
GH Chart
Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate
Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Guardant Health: Screening And MRD Are Just Getting Started
Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
Guardant Health Inc. (GH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Guardant Health Inc. ever had a stock split?
Guardant Health Inc. Profile
| Professional Services Industry | Industrials Sector | Helmy Eltoukhy CEO | XMEX Exchange | US40131M1099 ISIN |
| US Country | 2,498 Employees | - Last Dividend | - Last Split | 4 Oct 2018 IPO Date |
Overview
Guardant Health, Inc. is a pioneer in the precision oncology field, dedicated to enhancing cancer management through a comprehensive portfolio of blood and tissue tests, expansive data sets, and sophisticated analytics. Operating both within the United States and internationally, this company leverages cutting-edge technology to transform cancer care, making it more personalized and effective. Since its establishment in 2011, Guardant Health has been at the forefront of innovation in oncology, partnering with key industry players like Illumina, Inc., to push the boundaries of cancer research and treatment further.
Products and Services
- Guardant360: A liquid biopsy test that offers comprehensive genomic profiling of cancer from a simple blood draw, enabling non-invasive tumor genetic analysis.
- Guardant360 LDT: An extension of the Guardant360 service, tailored for more specific diagnostic needs through a laboratory-developed test approach.
- Guardant360 CDx Test: Designed as a companion diagnostic tool, this test helps in identifying patients who could benefit from specific cancer therapies based on their genetic markers.
- Guardant360 Response Test: This test monitors treatment response and disease progression, aiding in the timely adjustment of therapeutic strategies.
- Guardant360 TissueNext Test: Offers a more comprehensive genetic profile by combining blood-based and tissue-based genomic testing, ensuring no valuable data is missed.
- GuardantINFINITY Test: Aimed at providing a deeper understanding of tumor genetics over time, this test is crucial for uncovering resistance mechanisms and guiding long-term treatment plans.
- GuardantConnect: An integrated software solution that connects patients with actionable genetic alterations to clinical studies, improving accessibility to innovative treatments.
- GuardantOMNI Test: Focused on patients with advanced-stage cancer, this test screens for a broad array of genetic markers to inform treatment decisions.
- GuardantINFORM: A research platform that utilizes in-silico modeling to explore tumor evolution and resistance mechanisms across various cancers, aiding in the development of next-generation therapies.
- Shield Test: A novel approach for early cancer detection through the analysis of blood samples, aiming to improve survival rates through early intervention.
- Guardant Reveal Test: Specifically designed for early-stage cancer patients, this test guides adjuvant treatment selection to minimize recurrence risk.
- Smart Liquid Biopsy Platform: This innovative platform supports the development of precision oncology by offering flexible, scalable, and accurate liquid biopsy testing.
- Guardant Galaxy: An AI-backed digital pathology platform that enhances the detection of cancer biomarkers, leveraging artificial intelligence to improve diagnostic accuracy.
